

# **Original Research Article**

## **COVID-19 Vaccination: Early Estimates of a Relative Post-Interventional Case Fatality Risk**

### **Abstract**

Background: Recent epidemiological studies have demonstrated the efficacy of vaccines in reducing COVID-19 absolute case-fatality risks (CFRs) on a real-world global scale. However, these studies used cumulative (add-on) deaths and case accounts as nominators and denominators respectively.

This study aims to shed light on the relative post-COVID-19 vaccination non-cumulative CFR as a tool in monitoring the effectiveness of this intervention.

Methodology: We used post-vaccination non-cumulative counts of deaths and cases as at April 3, 2021, for a comparison of pre-COVID-19 vaccination data.

Sixteen countries/territories, which ran the COVID-19 vaccination program for at least a hundred days, were included in the study.

A matched paired t-test and a receiver operating characteristic (ROC) test were used for statistical analyses.

Results: **The relative post-COVID-19 vaccination CFRs are less than absolute (cumulative) CFRs and less than pre-vaccination CFRs.** The matched paired t-test for testing mean differences between pre-COVID-19 vaccination and relative post-COVID-19 vaccination CFRs show a *p*-value level of (0.126).

**The ROC test shows that the area under the curve was 0.391 for relative post-COVID-19 CFRs with an asymptotic significance of 0.291. The best COVID-19 cut-off CFR point was 1.6% which is an observed discriminator level between pre-vaccinated high CFRs and relative post-vaccinated CFRs lower level.**

Conclusions: The relative post-COVID-19-vaccination CFR is more sensitive than absolute CFR and can be used as a tool for measuring the effectiveness of COVID-19 vaccination coverage in reducing CFR in addition to standard parameters.

Recommendations: **The real world relative post-interventional CFR can be used as a new indicator to replace absolute (cumulative) post-interventional CFR as an early post-interventional assessment.**

Keywords: Case fatality risk; COVID-19; Vaccination; Relative post-COVID-19 vaccination CFR; Relative post-interventional CFR

**Abbreviations:**

COVID-19 : coronavirus disease 2019

CFR :case fatality risk

ROC :Receiver Operation Characteristic

(K-S) test : Kolmogorov–Smirnov test

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2

WHO : World Health Organization

## Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a strain of coronavirus that causes COVID-19 (coronavirus disease 2019)<sup>1</sup>, the illness responsible for the COVID-19 pandemic which was first identified in the city of Wuhan, Hubei, China in December 2019. The World Health Organization (WHO) declared the outbreak a public health emergency of international concern on 30 January 2020, and a pandemic on 11 March 2020. As of 17 April 2022, there was a total globally encountered deaths of 6,197,487 deaths and 504,180,613 cases, resulting a global case fatality risk (CFR) of 1.23%.<sup>2</sup>

The first rollout of COVID-19 vaccinations began in December 2020.<sup>3</sup> Early in 2021, the pandemic resulted in more than 131 million cases and more than 2.8 million deaths worldwide.<sup>4</sup> Several vaccines were authorized for public use in April 2021, to reduce infection and the severity of SARS-CoV-2 infection.<sup>5</sup> The most prominent of these vaccines were the Pfizer-BioNTech, Moderna, Oxford–AstraZeneca, Johnson and Johnson Janssen, and the CoronaVac, Sinovac Life Sciences vaccines.<sup>3</sup>

Various indicators were used to identify differences in rates of reported coronavirus disease 2019 (COVID-19) and severe COVID-19 outcomes, including hospitalizations and deaths.<sup>6</sup>

Among these, the COVID-19 case count and death indicators have been used as important decision-making guides for COVID-19-related lockdowns, reopening, mitigation, and response efforts.<sup>6</sup>

Monitoring COVID-19 vaccine effectiveness includes monitoring specific COVID-19 case counts and specific COVID-19 death counts in order to understand how the vaccine protects different age groups, protects specific groups, protects against new variants (e.g., Delta and Omicron), reduces the risk of infection, protects against milder COVID-19 illness, and prevents more serious outcomes, such as hospitalization or death.<sup>7</sup>

Case fatality risk (CFR) is calculated as the number of deaths from a disease, divided by the number of cases diagnosed with the same disease over a defined time and multiplied by 100.<sup>8</sup> Absolute CFR is typically used as a measure of disease severity and is often used for predicting disease courses or outcomes; it is estimated once an epidemic has ended after all cases have been resolved.<sup>9</sup> Absolute CFR estimates can be used to evaluate the effect of new treatments, with measures decreasing as treatments improve<sup>8</sup>

Few studies have described an absolute post-interventional CFR value in real-world COVID-19 pandemic monitoring. These studies usually use cumulative data to measure CFR changes across countries after public health interventions, such as the influence of lockdowns<sup>10</sup> and the influence of COVID-19 vaccinations on COVID-19 CFRs.<sup>11,12</sup>

This study attempts to measure the significance of the relative post-COVID-19 vaccination CFR as a tool to estimate the effect of vaccinations on COVID-19 CFR, taking into account estimates of non-cumulative new deaths and non-cumulative new cases rather than cumulative data used in standard CFR estimates.

## **Material and methods**

The sample in this study included 16 countries/territories that ran a COVID-19 vaccination program for at least a hundred days. Data was collected from the 4th of December 2020 to the 3d of April 2021.

Absolute (cumulative ) post-interventional CFR was measured as a percentage of total COVID-19 deaths divided by total COVID-19 confirmed cases.

Pre-vaccination CFR (CFR 1) was measured on day 1 of launching the vaccine campaign; relative post-vaccination CFR (CFR 3) on 3d of April 2021, as non-

cumulative COVID-19 confirmed deaths divided by non-cumulative COVID-19 cases; absolute CFR (CFR 3) was measured as cumulative deaths/COVID-19 accumulative confirmed cases on 3d of April 2021 multiplied by 100.

Data were retrieved from publicly available open-access databases, including the Our World in Data Coronavirus (COVID-19) vaccinations statistics and research database, the WHO coronavirus disease (COVID-19) dashboard, and the COVID-19 vaccines by country tracker (cnn.com) (see supplementary file).

We did not need to adjust for age as we tested the difference between relative post-vaccination CFR and pre-vaccination CFR for the same countries. Furthermore, we did not perform the 14-day lag **estimate of relative and absolute** post-vaccination CFRs on 3d of April 2021 as far as it was not considered in pre-vaccination CFR.

#### Statistical Methods:

A statistical data analysis was performed using the SPSS statistical package, version 22.0. It included a descriptive data analysis and inferential data analysis. The latter included: a one-sample Kolmogorov–Smirnov (K–S) test, a matched paired t-test, and a receiver operation characteristic (ROC) curve analysis. Through ROC curve analyses, the area under the curve was estimated, as was the 95% confidence interval, standard error, asymptotic significant level, and estimation of the cut-off point using:

- 1: an estimation of the low distance between the angle front to curve and the curve;
- 2: an estimation of the high distance between the curve's point and the one diameter point (Youden's index). **Youden's index integrates sensitivity and specificity information under circumstances that emphasize both sensitivity and specificity.**<sup>13</sup>

#### Results and Findings:

Table (1): Summary Statistics.

A- Summary statistics for absolute values		
Marker	value	%
Average* pre COVID-19-vaccination CFR (CFR 1) ** (on 1 <sup>st</sup> day of initiating vaccination)	2.362	100

Average* relative post-COVID- vaccination CFR (CFR2) *** (on 3 April 2021 ( non-ccumulative) excluding data on 1 <sup>st</sup> day of initiating vaccination)	2.195	92.930
Average* absolute COVID-19 CFR ( CFR 3****) (cumulative data on 3 April 2021)	2.283	96.655
Change ( difference ) in COVID-19 CFR ( CFR 2***-CFR 1**)	-0.167	-7.3149 %
CFR 2***/ CFR 1** Ratio	0.930	93
CFR 3**** / CFR 1** ratio	0.967	96.7

B- Summary statistics for COVID-19 CFR1 and CFR2 mean***** values								
Markers	No.	Mean	Std. D.	Std. E.	95% C.I. of Mean		Min.	Max.
					L.b.	U.b.		
CFR 1**	16	2.505	2.198	0.549	1.334	3.676	0.171	8.944
CFR 2***	16	1.913	2.116	0.529	0.785	3.040	0.140	9.263

\*Average COVID-19 CFR values: Summated no. of COVID-19 deaths for all countries/ summated no. of COVID-19 cases for all countries multiplied by 100.

\*\*(CFR1): pre-COVID-19 vaccination CFR.

\*\*\* CFR2: relative post-COVID-19 vaccination CFR

\*\*\*\*CFR3: Absolute CFR on April,3,2021

\*\*\*\*\*Mean COVID-19 CFR value: summation of COVID-19 CFR values/ no. of values.




Fig 1: Box-Whisker plot

Table 1 shows a reduction in the average CFR 2 and CFR 3 values. The reduction is more pronounced in the CFR 2 values. Tables 1B and C represent summary statistics for mean values and markers.

The average cumulative CFR (CFR 3) value (on 3d of April 2021) is higher than the total non-cumulative CFR 2 (at 3d of April 2021, excluding CFR on the first day of vaccinations being initiated). The average CFR 3/CFR 1 is higher than the average CFR 2/CFR 1.

The results show that the mean COVID-19 CFR marker recorded a high level of mean values on the first day that vaccinations started. The lower border value for 95% C.I. for COVID-19 CFR was lowered from 1.334 among CFR 1 values to 0.785 among CFR 2 values. The upper border was also lowered in relation to CFR 2 values, to some extent. CFR 2 is lower than CFR 1 (Figure 1).

Table (2): Normal distribution function test (Goodness of fit test) for studied markers.

One-Sample Kolmogorov-Smirnov Test			
Markers	No.	16	
	CFR 1 *: on day 1 of Starting Vaccine	Kolmogorov-Smirnov Z	0.896
		Asymptotic Sig. (2-tailed)	0.399

	C.S. <sup>(*)</sup>	NS
	No.	16
CFR 2 **: on 3d of April 2021	Kolmogorov-Smirnov Z	1.198
	Asymptotic Sig. (2-tailed)	0.113
	C.S. <sup>(*)</sup>	NS
Statistical Hypothesis: Ho: Markers are followed normal distribution function		
Test distributions are Normal for studied Markers		

<sup>(\*)</sup> NS: statistical non significance at  $P>0.05$ .

\*\*CFR 1: pre-COVID-19 vaccination CFR.

\*\*\* CFR 2: relative post-COVID-19 vaccination CFR

Table 2 represents a one-sample Kolmogorov–Smirnov test procedure, comparing the observed cumulative distribution function for the studied data with a specified theoretical distribution, which proposed a normal shape for the studied markers. The results show that the test's distributions for CFR 1 and CFR 2 are normal, since no significant levels are accounted for at ( $P>0.05$ ); this enables us to apply conventional methods of statistics.

Table (3): Matched Paired T-Test for testing mean differences between CFR1 and CFR2 .

Marker	Statistics			Matched Paired t-test		
	Mean diff.	Std. D.	Std. E.	t-test	d.f.	Sig. <sup>(*)</sup>
CFR 2 – CFR 1	-0.310	1.460	0.365	-1.622	15	0.126 (NS)

<sup>(\*)</sup> Statistical non-significant at  $P>0.05$

The results show that the p-value equals 0.126. The differences between CFR 1 and CFR 2 recorded a meaningful degenerated grade, rather than simply stating that a significant level of the area was not achieved and that there is no significant difference at  $P>0.05$  (Table 3).

Table (4): COVID-19 CFR marker's (Receiver Operation Characteristic-ROC) curve outcomes.

Marker	Cutoff Point( %)	Sen.	Spec.	Area	Std. Error	Asymp. Sig. (*)	Asymp. 95% C.I.	
							L.b.	U.b.
COVID-19 CFR	1.6015	0.625	0.375	0.391	0.102	0.291	0.191	0.590

(\*) Statistical non-significant at  $P > 0.05$ .

Table 4 shows the receiver operation characteristic (ROC) results. The estimated cut-off point was a CFR of 1.6015. It also shows a noticeable decrease in the lower bound of the 95% confidence interval.

Figure 2 represents a graphic ROC curve plot for studying the amount of degenerating outcomes in CFR 2 values in relation to CFR 1 values.




Figure (2): ROC curve plot for studied COVID-19 CFR markers CFR1 and CFR2.

## Discussion

The recorded p-value of 0.126 for the differences between CFR 1 and CFR 2 is set out in Table 3. . According to the matched paired t-test, this does not mean “not different from” or “similar” by any way and we do not reject the null hypothesis based on the 5% threshold. We did find that there was a definite difference in the CFR between two occasions; however, this difference did not meet our arbitrary cut-off for statistical significance.<sup>14</sup>

When considering the scientific, practical, and epidemiological significance of the different CFR findings, merely finding a *p-value* of >0.05 does not mean the study hypothesis is false right away;<sup>14</sup> rather, randomness or chance cannot be ruled out during a statistical explanation of our results, and the statistical evidence is insufficient to reject the null hypothesis.<sup>15</sup>

Indeed, according to the null hypothesis, the actual mean difference is zero; we can then conclude that the level of confidence in confirming the CFR difference across the two values (CFR 2–CFR 1), when interpreted in the context of the study design, is not less than 87.4% (as far as the p-value is 0.126).<sup>16,14</sup>

The mean CFR difference recorded by the 16 countries/territories at least 100 days after vaccination commenced (as at 3d of April 2021) was -0.310.

The ROC test shows that the area under the ROC curve was 0.391. This gives us an insight into the level of reduction in CFR 2 as at 3d of April 2021. Although this constitutes a substantial decrease in CFR, its asymptotic significance was just 0.291. We also expect a less significant reduction if we consider CFR 3 instead of CFR 2, because CFR 3 is higher than CFR 1 (Table 1). The best cut-off CFR point was 1.6, which had the highest true positive rate together with the lowest false positive rate. We expect higher cut-off points if CFR 3 is considered. Again, a statistical interpretation of the asymptotic significance value should consider the practical and epidemiological significance of the findings.

Consolidating our findings and conclusions is the lower border of 95% C.I. for COVID-19 CFR 2 was lower than corresponding CFR 1 border. Upper border for CFR 2 is lower than CFR 1 upper border to some extent. Furthermore , ROC analyses shows a noticeably low lower bound of the 95% confidence interval which further consolidate conclusions.

Data showed that the COVID-19 vaccine offers 52%–76% protection (according to vaccine type) against symptomatic COVID-19 from 12 days following

the first vaccine dose, which subsequently increased to 81–95% after administering the second dose.<sup>17</sup>

Compared with this study, a 10% increase in vaccine coverage was observed with a 7.6% reduction in the estimated accumulated absolute CFR according to the study of Liang LL et al., which evaluated the effectiveness of the COVID-19 vaccine during the later period of April 2021.<sup>11</sup> Furthermore, Raham TF also found that after the implementation of vaccination campaigns, the accumulated absolute CFR values for those countries achieving more than 19 doses/100 population were reduced.<sup>12</sup> Parallel to the introduction of these campaigns, the infection rate of the disease was reduced.<sup>4,12</sup> Thus, the observed reduced CFR after initiation of vaccination programs cannot simply be attributed to an increase in the denominator.

While the current study and the aforementioned two studies used real-world data sets, observational studies also tested the significance of vaccinations at a country level. They showed that mass vaccination reduced the risk of COVID-19 related deaths.<sup>18,19,20,21,22</sup>

The reduced CFR can be attributed to an increase in case detection, testing cover, and a decrease in the severity of cases, due to the effect of vaccinations or accumulative herd immunity caused by previous infections.

Countries throughout the world have reported very different case fatality estimates. Differences in mortality numbers can be caused by differences in the number of people tested, the demographic character of populations, characteristics of the healthcare system, and other factors, many of which remain unknown.<sup>6</sup>

CFR is a sensitive parameter to screening capacity; in Algeria, for example, where the first case was reported on February 25, 2020, CFR ranged from 2% to 15.8%.<sup>23,24,25</sup> The highest fatality rate was reported in early April 2020.<sup>26</sup>

Deficiencies in testing continued throughout the third wave, particularly with the appearance of the Delta variant and possibly during Omicron's emergence.<sup>27,28</sup> After partial improvements, the CFR screening capacity in Algeria<sup>25</sup> is currently 2.6%.<sup>29</sup> CFR variations, due to insufficient testing, are possibly applicable in many other countries.

Other possible factors influencing the pandemic include people's behavior and compliance towards isolation measures and lockdowns; changes in individual

behavior would directly (or indirectly) affect the spread of the virus by means of factors such as social distancing.<sup>30</sup>

Vaccination can lead to an early decrease in infection rates within the community. In the presence of a decrease in infection rates, such a decrease in CFR requires further attention. While the literature points to a possible increase of CFR through the sub-registration of cases,<sup>28</sup> few academic works point to a possible decrease in CFR after the reduction of attack rates.<sup>12,31,32,33</sup>

As this study assess a real-world CFR estimation, the dominator could account for vaccinated, unvaccinated, or previously infected people. Taking this into account and consideration, it differs from clinical studies by measuring the impact on the community, not on a selected sample.

Our study does have some limitations. One limitation is that the CFR is not constant; it can vary between populations and over time. In the absence of randomization, there could have been unmeasured differences in CFR between pre-COVID-19 vaccination and relative post-COVID-19 vaccination periods (e.g., a change in testing coverage or a change in the levels of adherence to non-pharmaceutical interventions), which might have confounded the compared CFR estimates.

Our findings suggest that the primary driver of reductions in the incidence of SARS-CoV-2 infections was a vaccination; this provides nationwide evidence of the beneficial public health impact of the COVID-19 vaccination campaign.

## **Conclusions:**

The relative post-COVID-19 vaccination CFR is less than the absolute (cumulative) CFR and less than the pre-vaccination CFR (p-value 0.126).

An ROC analysis consolidated this finding, and the area under the curve was 0.391 with an asymptotic significance of 0.291. The best COVID-19 cut-off CFR point was 1.6%, which is an observed discriminator level between pre-vaccinated high CFR and a relative post-vaccinated low CFR.

The relative post-COVID-19 vaccination CFR is better than the absolute CFR, and can be used as a tool for the early assessment of the effectiveness of COVID-19 vaccination coverage (or any intervention) on the reduction of CFR.

In this study we describe a relative post-COVID-19 vaccination CFR as a new tool for measuring the effectiveness of COVID-19 vaccination coverage on the reduction of CFR.

The relative post-COVID-19 vaccination CFR estimate is a useful indicator in the real world, replacing absolute (cumulative) post-COVID-19 CFR in addition to other parameters used, such as COVID-19 case count and death indicators.

This public health intervention indicator is more sensitive than the standard absolute CFR, since it can produce lower CFR values compared to the absolute CFR estimate.

### **Recommendations**

A real-world relative post-interventional CFR indicator can be used as a novel indicator to evaluate the impact of intervention and guide decision-making for COVID-19 reopening, mitigation, and response efforts.

### **Declarations**

- Availability of data and material : Attached as a supplementary file.

Acknowledgement: Statistical analysis and findings results were supervised by Bio-Statistician Prof. (Dr.) Abdulkhaleq Al-Naqeeb, College of Health and Medical Technology, Baghdad – Iraq.

### **Appendix (1): references for COVID-19 and population data**

- 1- [Coronavirus \(COVID-19\) Vaccinations - Statistics and Research - Our World in Data](#)
- 2- [WHO Coronavirus Disease \(COVID-19\) Dashboard With Vaccination Data | WHO Coronavirus \(COVID-19\) Dashboard With Vaccination Data](#)
- 3- [Covid-19 vaccine tracker: View vaccinations by country \(cnn.com\)](#)
- 4- Information and public services for the Island of Jersey  
[Coronavirus \(COVID-19\) \(gov.je\)](#)
- 5- [Population, total | Data \(worldbank.org\)](#)
- 6- <https://www.gov.je/Government/JerseyInFigures/Population/pages/population.aspx>
- 7- [GOV.GG](#) The official website for the States of Guernsey  
: <https://www.gov.gg/population>

Appendix (2)

Initial data including CFRs on 3 April 2021 , on day 1 of starting vaccine, and absolute CFR.

	Location	At day 1 of starting vaccination				3 April 2021			
		Population / 1000	Deaths	Cases	CFR 1*	Deaths	cases	CFR3* **	CFR2 **
1	Mexico	128,932.75	118598	1325915	8.944	203,664	2,244,268	9.074	9.263
2	China	1,410,929.36	4758	95064	5.005	4,851	102,838	4.717	1.196
3	Guernsey	63.385	13	291	4.467	14	821	1.705	0.189
4	United Kingdom	67,215.29	61434	1737694	3.535	126,764	4,350,270	2.914	2.5
5	Canada	38,005.24	13413	454851	2.952	23,002	987,918	2.328	1.799
6	Chile	19,116.21	16228	590914	2.746	23,421	1,011,485	2.316	1.710
7	Jersey	108.809	32	1637	1.954	69	3,228	2.138	2.325
8	United States	329,484.12	296840	15860675	1.871	547,884	30,238,692	1.812	1.746
9	Russia	144,104.08	42176	2402949	1.755	99,633	4,563,056	2.183	2.66
10	Saudi Arabia	34,813.87	6080	360353	1.687	6,684	391,325	1.708	1.950
11	Switzerl	8,636.90	6723	423731	1.586	9,654	600,331	1.608	1.66

	and								
12	Costa Rica	5,094.11	2037	159893	1.274	2,957	216,764	1.364	1.617
13	Serbia	6,908.22	2833	312253	0.907	5,345	605,406	0.883	0.857
14	Israel	9,216.90	3069	368617	0.833	6,216	833,269	0.746	0.677
15	Bahrain	1,701.58	349	89600	0.389	527	146,454	0.360	0.313
16	Qatar	2,881.06	243	142308	0.171	298	181,678	0.164	0.14
	Total	2,207,211.884	574,826	24,326,745	2.362	1,060,983	46,477,803	2.283	2.195

\*(CFR1): pre-vaccination CFR.

\*\* CFR2: relative post-vaccination CFR

\*\*\*CFR3: Absolute CFR on April,3,2021

## References

<sup>1</sup> Coronaviridae Study Group of the International Committee on Taxonomy of Viruses (April 2020). "The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2". *Nature Microbiology*. 5 (4): 536–544. doi:10.1038/s41564-020-0695-z.

<sup>2</sup> Johns Hopkins University.COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)".

<sup>3</sup> Al-Ali D, Elshafeey A, Mushannen M, *et al.* Cardiovascular and haematological events post COVID-19 vaccination: A systematic review. *J Cell Mol Med*. 2022 Feb;26(3):636-653. doi: 10.1111/jcmm.17137. Epub 2021 Dec 29. PMID: 34967105; PMCID: PMC8817142.

<sup>4</sup> Worldometer COVID-19 coronavirus pandemic.

<https://www.worldometers.info/coronavirus> [Ref list] Accessed 12 February 2022.

---

<sup>5</sup> Chen YT. The Effect of Vaccination Rates on the Infection of COVID-19 under the Vaccination Rate below the Herd Immunity Threshold. *Int J Environ Res Public Health*. 2021;18(14):7491. Published 2021 Jul 14. doi:10.3390/ijerph18147491

<sup>6</sup> Varela K, Scott B, Prather J, et al. Primary Indicators to Systematically Monitor COVID-19 Mitigation and Response - Kentucky, May 19-July 15, 2020. *MMWR Morb Mortal Wkly Rep*. 2020 Aug 28;69(34):1173-1176. doi: 10.15585/mmwr.mm6934e3. PMID: 32853188; PMCID: PMC7451968.

DOI: <http://dx.doi.org/10.15585/mmwr.mm6934e3external icon>.

<sup>7</sup> CDC. Monitoring COVID-19 Vaccine Effectiveness. How and Why CDC Tracks How Well the Vaccines Are Working. Updated Dec. 23, 2021

Accessed :20/4/2022

<https://www.cdc.gov/coronavirus/2019-ncov/vaccines/effectiveness/how-they-work.html>

<sup>8</sup> Harrington, Rebecca A.. case fatality rate. *Encyclopedia Britannica*, 5 May. 2020, <https://www.britannica.com/science/case-fatality-rate>. Accessed 12 February 2022.

<sup>9</sup>WHO. Estimating mortality from COVID-19. *Scientific Brief* .4 August 2020

<https://www.who.int/news-room/commentaries/detail/estimating-mortality-from-covid-19>

<sup>10</sup> Pachetti, M., Marini, B., Giudici, F. *et al*. Impact of lockdown on Covid-19 case fatality rate and viral mutations spread in 7 countries in Europe and North America. *J Transl Med* 18, 338 (2020). <https://doi.org/10.1186/s12967-020-02501-x>

<sup>11</sup> Liang LL, Kuo HS, Ho HJ, Wu CY. COVID-19 vaccinations are associated with reduced fatality rates: Evidence from cross-county quasi-experiments. *J Glob Health*. 2021;11:05019. Published 2021 Jul 17. doi:10.7189/jogh.11.05019

<sup>12</sup> Raham, T. F. Influence of COVID-19 Vaccination Coverage on Case Fatality Risk. *Asian Journal of Research in Infectious Diseases*. 2022. 9(2), 21-31. <https://doi.org/10.9734/ajrid/2022/v9i230265>

<sup>13</sup> Youden WJ. *Cancer*. Vol. 3. 1950. Index for rating diagnostic tests; pp. 32–35.

<sup>14</sup> Andrade C. The P Value and Statistical Significance: Misunderstandings, Explanations, Challenges, and Alternatives. *Indian J Psychol Med*. 2019;41(3):210-215. doi:10.4103/IJPSYM.IJPSYM\_193\_19

<sup>15</sup> Kim J, Bang H. Three common misuses of P values. *Dent Hypotheses*. 2016 Jul-Sep;7(3):73-80. doi: 10.4103/2155-8213.190481. Epub 2016 Sep 14. PMID: 27695640; PMCID: PMC5042133.

<sup>16</sup> Nordness RJ. *Epidemiology and Biostatistics Secrets*. Mosby Elsevier. Philadelphia. 2006. P156.

<sup>17</sup> Joshi G, Borah P, Thakur S. *et al* . Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?. *Human vaccines & immunotherapeutics*. 2021;17(12) :4714–4740. <https://doi.org/10.1080/21645515.2021.1995283>

<sup>18</sup> Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. *N Engl J Med*. 2021;384(15):1412-23. Medline:33626250 doi:10.1056/NEJMoa2101765

<sup>19</sup> Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths

---

following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. *Lancet*. 2021;397:1819-29. Medline:33964222 doi:10.1016/S0140-6736(21)00947-8

<sup>20</sup> Amit S, Regev-Yochay G, Afek A, Kreiss Y, Leshem E. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. *Lancet*. 2021;397:875-7. Medline:33610193 doi:10.1016/S0140-6736(21)00448-7

<sup>21</sup> Chodick G, Tene L, Patalon T, et al. Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization. *JAMA Netw Open*. 2021;4:e2115985. Medline:34097044 doi:10.1001/jamanetworkopen.2021.15985

<sup>22</sup> Moghadas SM, Vilches TN, Zhang K, Wells CR, Shoukat A, Singer BH, et al. The impact of vaccination on coronavirus disease 2019 (COVID-19) outbreaks in the United States. *Clin Infect Dis*. 2021;ciab079. Medline:33515252 doi:10.1093/cid/ciab079

<sup>23</sup> Algerian health and hospital reform minister: Carte épidémiologique. [Accessed April 16, 2022]. <https://www.covid19.gov.dz/carte/> [Ref list]

<sup>24</sup> Aouissi, H. A., & Belhaouchet, I. (2021). What about rheumatic diseases and COVID 19?. *New microbes and new infections*, 41, 100846. <https://doi.org/10.1016/j.nmni.2021.100846>

<sup>25</sup> Lounis M. (2021). COVID-19: Why Algeria's Case Fatality Rate Seems to be Among the Highest in the World?. *The Eurasian journal of medicine*, 53(2), 160–161. <https://doi.org/10.5152/eurasianjmed.2021.20192>

<sup>26</sup> WHO African region. COVID-19 External Situation Report. Date of issue: 15 April 2020. Accessed date: April 20, 2022. [https://apps.who.int/iris/bitstream/handle/10665/331763/SITREP\\_COVID-19\\_WHOAFRO\\_20200415-eng.pdf](https://apps.who.int/iris/bitstream/handle/10665/331763/SITREP_COVID-19_WHOAFRO_20200415-eng.pdf)

<sup>27</sup> Aouissi H. A. (2021). Algeria's preparedness for Omicron variant and for the fourth wave of COVID-19. *Global health & medicine*, 3(6), 413–414. <https://doi.org/10.35772/ghm.2021.01117>

<sup>28</sup> Leveau CM, Aouissi HA, Kebaili FK. Spatial diffusion of COVID-19 in Algeria during the third wave. *Geojournal*. 2022 .1-6. DOI: 10.1007/s10708-022-10608-5. PMID: 35261429; PMCID: PMC8893245.

<sup>29</sup> Johns Hopkins Coronavirus Resource Center. <https://coronavirus.jhu.edu/data/mortality> accessed :April 20, 2022

<sup>30</sup> Aouissi, HA, Ababsa M, Leveau *et al.* . Beyond vaccination: A Cross-Sectional Study of the importance of Behavioral and Native Factors on COVID-19 Infection and Severity. *medRxiv*. medRxiv 2022.01.23.22269214; doi: <https://doi.org/10.1101/2022.01.23.22269214>

<sup>31</sup> Al-Naqeeb A. A. A. , Raham TF, Case Fatality Rate Components Based Scenarios for COVID-19 Lockdown. *Journal of Community Medicine and Public Health*. 2021 5 (3), 1-10

<sup>32</sup> Raham TF. Covid-19 High Attack Rate Can Lead to High Case Fatality Rate. *American J Epidemiol Public Health*. 2021 April 27;5(2): 045-049. doi: 10.37871/ajeph.id49

<sup>33</sup> Raham, TF. Epidemiological Philosophy of Pandemics. *International Journal of Community Medicine and Public Health (IJCPMH)*. 2021;8(7);2021



UNDER PEER REVIEW